Wang Dong, Mehrabi Nasab Entezar, Athari Seyyed Shamsadin
Department of Internal Medicine of Traditional Chinese Medicine, People's Hospital of Yanting County, Sichuan 621600, China.
Cardiologist, Department of Cardiology, School of Medicine, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
Saudi J Biol Sci. 2021 Aug;28(8):4311-4317. doi: 10.1016/j.sjbs.2021.04.009. Epub 2021 Apr 20.
Asthma as chronic airway disease has high prevalence in children and imbalance of Th1/Th2 is a critical mechanism in pathogenesis of the asthma. Baicalein as a cell protective and anti-inflammatory flavonoid may have anti-asthma effect. Therefore, for better using lung, baicalein was used in chitosan-nanoparticle as anti-asthma treatment. Baicalein was loaded and encapsulated in chitosan nanoparticle. The morphology, physical characters (particle size, zeta potential and FT-IR) were analyzed. Drug encapsulation and loading capacity, accumulative release-time were studied. After asthma model producing, the mice were treated with L-B-NP and E-B-NP. At least, MCh challenge test, Cytokines measurement and Lung Histopathology were done. Nanoparticles had average size 285 ± 25 nm with negative charge -2.5 mV. The L-B-NP decreased penh value and E-B-NP decreased inflammation. Both nanoparticles increased IL-12 and decreased IL-5. Also, L-B-NP decreased mucus secretion in bronchi. L-B-NP and E-B-NP control immune-allergo-inflammatory response of asthma. L-B-NP controlled AHR and E-B-NP controlled inflammation that can be used as controlling anti-asthma drug.
哮喘作为一种慢性气道疾病在儿童中具有很高的患病率，Th1/Th2失衡是哮喘发病机制中的关键机制。黄芩苷作为一种具有细胞保护和抗炎作用的黄酮类化合物可能具有抗哮喘作用。因此，为了更好地利用肺部，黄芩苷被用于壳聚糖纳米颗粒中进行抗哮喘治疗。黄芩苷被负载并包裹在壳聚糖纳米颗粒中。分析了其形态、物理特性（粒径、zeta电位和傅里叶变换红外光谱）。研究了药物包封率和载药量、累积释放时间。制备哮喘模型后，用L-B-NP和E-B-NP对小鼠进行治疗。至少进行了乙酰甲胆碱激发试验、细胞因子检测和肺组织病理学检查。纳米颗粒的平均粒径为285±25nm，带-2.5mV的负电荷。L-B-NP降低了气道阻力值，E-B-NP减轻了炎症。两种纳米颗粒均增加了白细胞介素-12并降低了白细胞介素-5。此外，L-B-NP减少了支气管中的黏液分泌。L-B-NP和E-B-NP可控制哮喘的免疫过敏炎症反应。L-B-NP可控制气道高反应性，E-B-NP可控制炎症，可作为抗哮喘控制药物使用。
